natgillin/translations-raw huggingface dataset:
The major bleeding results for prespecified subgroups including CHADS2 score, age, body weight, gender, status of renal function, prior stroke or TIA and diabetes were consistent with the results for the overall population studied in the trial.
Rezultati krvarenja za unaprijed određene podskupine s obzirom na rezultat na ljestvici CHADS2, dob, tjelesnu težinu, spol, status bubrežne funkcije, pretrpljen moždani udar ili tranzitornu ishemijsku ataku i šećernu bolest, bili su u skladu s rezultatima za cjelokupnu populaciju obuhvaćenu ispitivanjem.
The major circulating inactive metabolite is the glucuronide conjugate of O-demethylated apremilast (M12).
Glavni cirkulirajući neaktivni metabolit je glukunoridni konjugat O-demetiliranog apremilasta (M12).
The major circulating metabolite of doxorubicin, doxorubicinol, is formed via aldo-keto-reductase.
Glavni cirkulirajući metabolit doksorubicina, doksorubicinol stvara se djelovanjem aldo-keto-reduktaze.
The major compounds excreted in urine are unchanged lacosamide (approximately 40% of the dose) and its O-desmethyl metabolite less than 30%.
Glavninu sastojaka izlučenih mokraćom čine nepromijenjen lakozamid (otprilike 40% doze) i njegov O-dezmetilni metabolit manje od 30%.
The major degradation product of pravastatin is the 3-α- hydroxy isomeric metabolite.
Glavni produkt razgradnje pravastatina je 3-α-hidroksi izomerni metabolit.
The major dose limiting toxicities of lenalidomide include neutropenia and thrombocytopenia.
Glavne toksičnosti koje ograničavaju dozu lenalidomida uključuju neutropeniju i trombocitopeniju.
The major exclusion criteria for patients were documented peptic ulcer disease within the previous months; prior intracerebral hemorrhage; significant thrombocytopenia (platelet count < 50 x 109/l); requirement for clopidogrel or oral anticoagulants (OAC); or intolerance to any of the two compounds.
Glavni kriterij za isključivanje bolesnika bili su dokumentirani peptički ulkus unutar zadnjih 6 mjeseci, prethodno intracerbralno krvarenje, značajna trombocitopenija (broj trombocita <50 x 109/l), potreba za klopidogrelom ili oralnim antikoagulansima ili netolerancija prema bilo kojoj od dvije djelatne tvari.
The major metabolic routes in dogs are hydroxylation of a methyl substituent and further oxidation to a carboxylic acid or O-glucuronidation of the hydroxylated product.
Glavni metabolički putovi u pasa: hidroksilacija zamjene metila i daljnja oksidacija u karboksilnu kiselinu ili O-glukuronidacija hidroksiliranog produkta.
The major metabolite in plasma is formed by O- dealkylation, referred to as metabolite M-II, and the minor metabolite is formed by decarboxylation, referred to as metabolite M-I.
Glavni metabolit u plazmi stvara se O- dealkilacijom i naziva se metabolit M-II, dok se sporedni metabolit stvara dekarboksilacijom i naziva se metabolit M-I.
The major metabolite NAP226- 90 also did not show a genotoxic potential.
Glavni metabolit NAP226-90 također nije pokazao genotoksični potencijal.
The major metabolite of ertapenem is the ring-opened derivative formed by dehydropeptidase-I-mediated hydrolysis of the beta-lactam ring.
Glavni metabolit ertapenema je derivat otvorenog prstena nastao hidrolizom beta- laktamskog prstena posredovanom dehidropeptidazom-I.
The major metabolite,
Glavni metabolit,
The major metabolites found in all species were the 5-hydroxy- and 5-carboxy- metabolites and the oxalyl- metabolite.
Osnovni metaboliti nađeni kod svih vrsta bili su 5-hidroksi- i 5- karboksi-metaboliti te oksalil-metabolit.
The major metabolites found in all species were the 5-hydroxy- and 5-carboxy- metabolites and the oxalyl- metabolite.
Osnovni metaboliti nađeni u svih vrsta bili su 5-hidroksi- i 5- karboksi-metaboliti te oksalil-metabolit.
The major metabolites found in all species were the 5-hydroxy- and 5-carboxy- metabolites and the oxalyl-metabolite.
Osnovni metaboliti nađeni u svih vrsta bili su 5-hidroksi- i 5-karboksi-metaboliti te oksalil-metabolit.
The major metabolites found in all species were the 5-hydroxy- and 5-carboxy-metabolites and the oxalyl-metabolite.
Glavni metaboliti koji su pronađeni u svih vrsta su 5-hidroksi i 5-karboksi metaboliti te oksalil-metaboliti.
The major metabolites found in all species were the 5-hydroxy- and 5-carboxy-metabolites and the oxalyl-metabolite.
Glavni metaboliti pronađeni kod svih vrsta bili su 5-hidroksi i 5-karboksi metaboliti te oksalil-metabolit.
The major route of elimination is the excretion of unchanged fluralaner in faeces (~90% of the dose).
Glavni put eliminacije je izlučivanje nepromijenjenog fluralanera u fecesu (~ 90% doze).
The major route of elimination of drug related radioactivity after oral administration of [14C] nintedanib was via faecal/biliary excretion (93.4% of dose,
Glavni put eliminacije radioaktivnosti vezane uz lijek nakon peroralne primjene [14C] nintedaniba bio je izlučivanjem stolicom/putem žuči (93,4% doze, 2,61% gCV).
The major route of excretion of radiolabeled bazedoxifene is the faeces, and less than 1% of the dose is eliminated in urine.
Glavni put izlučivanja radioaktivno obilježenog bazedoksifena je putem stolice, a manje od 1% doze eliminira se urinom.
The major route of excretion was via the urine (>90%) while faecal excretion was minor.
Glavni način izlučivanja bio je mokraćom (> 90%), dok je izlučivanje stolicom bilo manje zastupljeno.
The major secondary endpoint was the proportion of patients who achieved a sPGA score of clear (0) or almost clear (1) at Week 16.
Glavni sekundarni ishod bio je udio bolesnika kojima je rezultat sPGA bio 'bez znakova psorijaze' (0) ili gotovo bez znakova (1) u 16. tjednu.
The major target organs were the lymphoid system (lymphopenia and lymphoid atrophy), lungs (increased weight, smooth muscle hypertrophy at the bronchio-alveolar junction), and heart (negative chronotropic effect, increase in blood pressure, perivascular changes and myocardial degeneration) in several species; blood vessels (vasculopathy) in rats only at doses of 0.15 mg/kg and higher in a 2- year study, representing an approximate 4-fold margin based on the human systemic exposure (AUC) at a daily dose of 0.5 mg.
Glavni ciljni organi bili su limfoidni sustav (limfopenija i limfoidna atrofija), pluća (povećana težina, hipertrofija glatkih mišića na spoju bronha i alveola) i srce (negativni kronotropni učinak, povećanje krvnog tlaka, perivaskularne promjene i degeneracija miokarda) kod nekoliko životinjskih vrsta; krvne žile (vaskulopatija) bile su zahvaćene samo u štakora pri dozama od 0,15 mg/kg i višim u dvogodišnjem ispitivanju, što predstavlja približno četverostruko veću vrijednost u odnosu na sistemsku ekspoziciju (AUC) kod ljudi pri svakodnevnoj dozi od 0,5 mg.
The majority (70.4%) of patients had Stable Disease as a best response (based on Investigator’s assessment using RECIST criteria) and 29.6% patients had Progressive Disease as their best overall response.
Glavnina bolesnika (70,4 %) imala je stabilnu bolest kao najbolji odgovor (bazirano na ocjeni ispitivača korištenjem RECIST kriterija) a 29,6 % bolesnika imalo je progresiju bolesti kao najbolji ukupni odgovor.
The majority (70/80) of the recorded VTE events were venographically detected non-symptomatic cases of DVT.
Većina (70/80) zabilježenih VTE bili su venografski detektirani asimptomatski slučajevi DVT.
The majority (75%) of patients had M1c stage disease at study entry.
Većina (75%) bolesnika je pri uključivanju u ispitivanje imala bolest stadija M1c.
The majority (95%) of IRRs occurred at the first infusion.
Većina (95%) reakcija na infuziju nastupila je tijekom prve infuzije.
The majority had hypertension (86%) and structural heart disease (60%) (including coronary artery disease: 30%; congestive heart failure (CHF): 30%; LVEF<45%: 12%).
Većina je imala hipertenziju (86%) i strukturnu bolest srca (60%) (uključujući bolest koronarnih arterija: 30%; kongestivno zatajenje srca: 30%; ejekcijsku frakciju lijeve klijetke < 45%: 12%).
The majority had spinal pain (n = 134), especially failed back surgery (n = 110); a lower proportion had neuropathy (n = 36).
Većina ih je imala bol u kralježnici (n = 134), a osobito oni s neuspjelim kirurškim zahvatom kralježnice (n = 110); manji je broj imao neuropatiju (n = 36).
The majority of ADRs reported were of Grade 1 or 2 severity. the most common National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade ≥ 3 ADRs (> 2%) were thrombocytopenia, increased transaminases, anaemia, neutropenia, fatigue, hypokalaemia, musculoskeletal pain and haemorrhage.
Većina prijavljenih nuspojava lijeka bila je stupnja težine 1 ili 2. najčešće nuspojave lijeka stupnja ≥ 3 (> 2%) prema Zajedničkim kriterijima terminologije za nuspojave Nacionalnog instituta za rak (NCI-CTCAE) bile su trombocitopenija, povišene vrijednosti transaminaza, anemija, neutropenija, umor, hipokalijemija, bol u mišićno-koštanom sustavu te krvarenje.
The majority of adverse drug reactions were mild to moderate, they usually start early in therapy and most tended to disappear even as therapy was continued.
Međutim, većina nuspojava bila je blaga do umjerena, one obično počinju na početku liječenja te većinom postupno nestaju čak i s nastavkom terapije.
The majority of adverse drug reactions were mild to moderate, they usually start early in therapy and most tended to disappear even as therapy was continued.
Međutim, većina nuspojava bila je blaga do umjerena, one obično počinju na početku liječenja, te većinom postupno nestaju čak i s nastavkom terapije.
The majority of adverse drug reactions were mild to moderate, they usually start early in therapy and most tended to disappear even as therapy was continued.
Većina nuspojava lijeka bila je blaga do umjerena, one su obično počinjale u ranoj fazi liječenja te većinom postupno nestajale s nastavkom terapije.
The majority of adverse reactions are mild and transient.
Većina nuspojava su blage i prolazne.
The majority of adverse reactions in clinical trials were IRs, which are defined as reactions occurring after initiation of infusion until the end of the day following the infusion.
Većina nuspojava u kliničkim ispitivanjima bile su reakcije povezane s infuzijom koje se definiraju kao reakcije koje su se dogodile nakon početka infuzije pa do isteka sljedećeg dana.
The majority of adverse reactions presented in Table 3 were of grade 1 severity in Viekirax and dasabuvir- containing regimens.
Većina nuspojava navedenih u Tablici 3 bila je 1. stupnja težine za Viekirax te za kombinacije koje sadrže dasabuvir.
The majority of adverse reactions reported were of Grade 1 or 2 severity.
Većina prijavljenih nuspojava bila je 1. ili 2. stupnja težine.
The majority of application site reactions were mild or moderate in intensity, limited to the application areas and resulted in discontinuation of Neupro in 7.2% of subjects.
Većina reakcija na mjestu primjene bila je blagog ili umjerenog intenziteta, ograničena na područja primjene, a 7,2% ispitanika zbog njih je prekinulo primjenu Neupra.
The majority of application site reactions were mild or moderate in intensity, limited to the application areas and resulted in discontinuation of treatment with Leganto in only 4.3% of all subjects receiving Leganto.
Većina reakcija na mjestu primjene bila je blagog ili umjerenog intenziteta, ograničena na područja primjene, a samo je 4,3% ispitanika koji su primali Leganto zbog njih je prekinulo liječenje Legantom.
The majority of application site reactions were mild or moderate in intensity, limited to the application areas and resulted in discontinuation of treatment with Neupro in only 4.3% of all subjects receiving Neupro.
Većina reakcija na mjestu primjene bila je blagog ili umjerenog intenziteta, ograničena na područja primjene, a samo je 4,3% ispitanika koji su primali Neupro zbog njih je prekinulo liječenje Neuprom.
The majority of cases have occurred in adolescent and young adult males with nearly all on comcomitant treatment with azathioprine (AZA) or
Većina se slučajeva dogodila u adolescenata i mlađih odraslih muškaraca, od kojih su gotovo svi istodobno primali terapiju azatioprinom (AZA) ili
The majority of cases occurred in patients who had received prior or concomitant treatment with intravenous bisphosphonates, for which ONJ is an identified risk.
Većina je slučajeva zabilježena u bolesnika koji su prethodno ili istodobno liječeni intravenski primijenjenim bisfosfonatima, za koje je osteonekroza čeljusti utvrđen rizik.
The majority of cases were Grade 1 in severity reported in 21.9% (378/1728) of patients.
Većina slučajeva bila je 1. stupnja težine, a prijavljeni su u 21,9% (378/1728) bolesnika.
The majority of cases were Grade 1 or 2 in severity reported in 0.7% (12/1728) and 1.7% (29/1728) of patients respectively.
Većina slučajeva bila je 1. ili 2. stupnja težine, a prijavljeni su u 0,7% (12/1728) odnosno 1,7% (29/1728) bolesnika.
The majority of cases were Grade 1 or 2 in severity reported in 3.6% (62/1728) and 4.9% (85/1728) of patients respectively.
Većina slučajeva bila je 1. ili 2. stupnja težine, a prijavljeni su u 3,6% (62/1728) odnosno 4,9% (85/1728) bolesnika.
The majority of cases were Grade 1 or 2 in severity reported in 3.9% (68/1728) and 1.3% (22/1728) of patients respectively.
Većina slučajeva bila je 1. ili 2. stupnja težine, a prijavljeni su u 3,9% (68/1728) odnosno 1,3% (22/1728) bolesnika.
The majority of cases were Grade 1 or 2 in severity reported in 9.0% (156/1728) and 3.0% (52/1728) of patients respectively.
Većina slučajeva bila je 1. ili 2. stupnja težine, a prijavljeni su u 9,0% (156/1728) odnosno 3,0% (52/1728) bolesnika.
The majority of events resolved after treatment interruption.
Većina događaja povukla se nakon prekida liječenja.
The majority of events were asymptomatic distal DVT.
U većini slučajeva radilo se o asimptomatskoj DVT.
The majority of events were Grade 1 or 2 and non-serious (12% of patients in the Cotellic plus vemurafenib arm vs 7% patients in the placebo plus vemurafenib arm).
Većina događaja bila je 1. ili 2. stupnja težine te nije bila ozbiljna (12% bolesnika u skupini liječenoj lijekom Cotellic plus vemurafenibom naspram 7% bolesnika u skupini koja je primala placebo plus vemurafenib).
The majority of headaches reported with CIALIS once-a- day dosing are experienced within the first 10 to 30 days of starting treatment.
U većini se slučajeva glavobolja prijavljena kod primjene lijeka CIALIS jedanput na dan javila unutar prvih 10 do 30 dana nakon početka liječenja.
The majority of imatinib-intolerant patients with chronic phase CML were able to tolerate treatment with SPRYCEL.
Većina bolesnika s KML u kroničnoj fazi koji nisu podnosili imatinib podnijela je liječenje lijekom SPRYCEL.
The majority of infections were non-serious and mild to moderate in severity, most of which did not necessitate treatment discontinuation.
Većina infekcija nije bila ozbiljna te je bila blage do umjerene težine, te većina njih nije zahtijevala prekid liječenja.
The majority of infusion reactions were Grade 1 or Grade 2 in severity.
Većina reakcija na infuziju bila je 1. ili 2. stupnja težine.
The majority of IRRs were mild or moderate in intensity and <1% resulted in discontinuation of study treatment.
Većina RPI bilo je blagog do umjerenog intenziteta, a <1% reakcija rezultiralo je prekidom ispitivanog liječenja.
The majority of methicillin-resistant S. aureus (MRSA) express cMLSB.
Većina sojeva S. aureus rezistentnih na meticilin (MRSA) izražava rezistenciju tipa cMLSB.
The majority of orlistat overdose cases received during post-marketing reported either no adverse events or adverse events that are similar to those reported with recommended dose.
U većini prijavljenih slučajeva predoziranja orlistatom u razdoblju nakon stavljanja lijeka u promet nisu prijavljene nikakve nuspojave ili su prijavljene nuspojave bile slične onima za vrijeme uzimanja lijeka u preporučenoj dozi.
The majority of orlistat overdose cases received during post-marketing reported either no adverse reactions or adverse reactions that are similar to those reported with recommended doses of orlistat.
U većini slučajeva, predoziranja orlistatom, prijavljenih nakon stavljanja lijeka u promet nije bilo nuspojava ili su bile slične onima prijavljenima pri uzimanju preporučenih doza orlistata.
The majority of paediatric patients achieved improvement in clinical symptoms and objective markers of inflammation (e.g.
Većina pedijatrijskih bolesnika postigla je poboljšanje kliničkih simptoma i objektivnih markera upale (npr.
The majority of patients (58%) had LDL- cholesterol > 190 mg/dl at study entry, and 24% of patients with LDL-cholesterol > 190 mg/dl were on lipid lowering medicinal products.
Većina bolesnika (58%) imala je LDL kolesterol > 190 mg/dl pri ulasku u ispitivanje, a 24% bolesnika s LDL kolesterolom > 190 mg/dl uzimalo je lijekove za snižavanje razine lipida.
The majority of patients (83%) had visceral metastases at baseline.
Većina bolesnika (83%) je na početku liječenja imala visceralne metastaze.
The majority of patients do not require termination of TRISENOX therapy during treatment of the APL differentiation syndrome.
Većina bolesnika ne zahtijeva prekid liječenja TRISENOXOM tijekom liječenja sindroma diferencijacije APL-a.
The majority of patients experience chills (89%), fever (85%) and fatigue (53%).
Većina bolesnika iskusila je zimicu (89%), vrućicu (85%) i umor (53%).
The majority of patients had a long history of CML that included extensive prior treatment with other antineoplastic agents, including imatinib, hydroxyurea, interferon, and some had even failed organ transplant (Table 9).
Većina bolesnika dulje je bolovala od KML-a, uz opsežno prethodno liječenje antineoplasticima, uključujući imatinib, hidroksiureju, interferon, dok je u nekih bolesnika učinjena transplantacija koštane srži ali neuspješno (Tablica 9).
The majority of patients had either favourable (39 %) or intermediate (54 %), MSKCC (Memorial Sloan Kettering Cancer Centre) / Motzer prognostic factors.
Kod većine su bolesnika MSKCC (Memorial Sloan Kettering Cancer Centre) / Motzer prognostički faktori bili povoljni (39%) ili osrednji (54%).
The majority of patients had EOC (87.7%) followed by PPC (6.9%) and FTC (3.7%) or a mixture of the three origins (1.7%).
Većina bolesnica bolovala je od epitelnog karcinoma jajnika (87,7%), nakon kojega po učestalosti slijede primarni peritonealni karcinom (6,9%) i karcinom jajovoda (3,7%) ili kombinacija tih triju bolesti (1,7%).
The majority of patients had no change in the toxicity grade of any laboratory parameter during the study except for those listed in Table 4.
U većine bolesnika tijekom ispitivanja nije došlo do promjene stupnja toksičnosti bilo kojeg laboratorijskog parametra, osim onih navedenih u Tablici 4.
The majority of patients had received MabThera in combination with chemotherapy or as part of a hematopoietic stem cell transplant.
Većina je bolesnika primala lijek MabThera u kombinaciji s kemoterapijom ili u sklopu presađivanja hematopoetskih matičnih stanica.
The majority of patients had relapsing–remitting multiple sclerosis (91.5%), but a subgroup of patients had secondary progressive (4.7%) or progressive relapsing multiple sclerosis (3.9%).
Većina bolesnika imala je relapsno-remitirajuću multiplu sklerozu (91,5%), a jedna podskupina bolesnika imala je sekundarnu progresivnu (4,7%) ili progresivnu relapsnu multiplu sklerozu (3,9%).
The majority of patients had relapsing–remitting multiple sclerosis (97.5%), but a subgroup of patients had secondary progressive (0.8%) or progressive relapsing multiple sclerosis (1.7%).
Većina bolesnika imala je relapsno-remitirajuću multiplu sklerozu (97,5%), a jedna podskupina bolesnika imala je sekundarnu progresivnu (0,8%) ili progresivnu relapsnu multiplu sklerozu (1,7%).
The majority of patients in both arms had an ECOG Performance Status (PS) of 0 (CT: 56.4% vs.
Većina bolesnica u obje skupine imala je ECOG status općeg stanja 0 (KT: 56,4% naspram KT+BV: 61,2%).
The majority of patients in the phase 3 program were taking background lipid-modifying therapy consisting of a maximally tolerated dose of statin, with or without other lipid- modifying therapies, and were at high or very high cardiovascular (CV) risk.
Većina bolesnika u programu ispitivanja faze 3 uzimala je osnovnu terapiju koja modificira lipide, koja se sastojala od maksimalne podnošljive doze statina u kombinaciji s drugim terapijama koje modificiraju lipide ili bez njih, te je u njih postojao visok ili vrlo visok kardiovaskularni (KV) rizik.
The majority of patients in these studies were using immunomodulatory medicines.
Većina bolesnika u ovim ispitivanjima su također koristili imunomodulacijske lijekove.
The majority of patients included had an ECOG performance status of ≤ 1.
Kod većine uključenih bolesnika ECOG indeks bio je ≤ 1.
The majority of patients included in studies with Kyprolis received antiviral prophylaxis; due to this fact it is not possible to calculate the true incidence of herpes zoster infection in patients treated with Kyprolis.
Većina bolesnika uključenih u ispitivanja s lijekom Kyprolis primila je antivirusno profilaktičko liječenje; zbog toga nije moguće izračunati stvarnu incidenciju infekcije virusom herpes zoster u bolesnika liječenih lijekom Kyprolis.
The majority of patients included in the study were White (87% in all three arms); the median age was 60 years in CPP and CPB15 arms and 59 years in CPB15+ arm; and 29% of patients in CPP or CPB15 and 26% in CPB15+ were over 65 years of age.
Većina bolesnica obuhvaćenih ispitivanjem bile su bijele rase (87% u sve tri skupine), medijan dobi iznosio je 60 godina u skupinama CPP i CPB15, a 59 godina u skupini CPB15+, dok je 29% bolesnica u skupinama CPP i CPB15 te 26% u skupini CPB15+ bilo starije od 65 godina.
The majority of patients included in the study were White (96%), the median age was 57 years in both treatment arms, 25% of patients in each treatment arm were 65 years of age or over, and approximately 50% of patients had an ECOG PS of 1; 7% of patients in each treatment arm had an ECOG PS of 2.
Većina bolesnica obuhvaćenih ispitivanjem bila je bijele rase (96%), medijan dobi u obje je skupine iznosio 57 godina, a 25% bolesnica u svakoj skupini imalo je 65 ili više godina.
The majority of patients treated with Xultophy in these studies achieved control of their blood glucose (HbA1c below 7.0%) and many achieved HbA1c below 6.5%.
Većina bolesnika liječenih lijekom Xultophy u ovim ispitivanjima postigla je kontrolu razine glukoze u krvi (ciljne razine HbA1c manje od 7,0 %), a mnogi su postigli HbA1c manji od 6,5 %.
The majority of patients were Caucasian (86.3%) and female (89.2%), with a mean age of 59.4 years (range: 18 to 88 years).
Većinu bolesnika činili su bijelci (86,3%) i žene (89,2%), prosječne dobi od 59,4 godina (raspon: od 18 do 88 godina).
The majority of patients were diagnosed as primary pulmonary hypertension (72%) and were in WHO functional class III (84%).
Većina bolesnika imala je dijagnozu plućne arterijske hipertenzije (72%) te su bili u skupini III prema WHO funkcijskom stanju (84%).
The majority of patients were diagnosed with idiopathic or heritable pulmonary arterial hypertension (61%).
Većina bolesnika imala je dijagnozu idiopatske ili nasljedne plućne arterijske hipertenzije (61%).
The majority of patients were HCV genotype 1 (64%) and had bridging fibrosis/cirrhosis.
Većina bolesnika imala je HCV genotip 1 (64%) i premoštavajuću ('bridging') fibrozu/cirozu.
The majority of patients were male (59%) and white (79%); the median age for the overall population was 64 years (min, max: 35, 87 years).
Većina bolesnika bili su muškarci (59%) i bijelci (79%); medijan dobi u populaciji bio je 64 godine (raspon 35-87 godina).
The majority of patients were non-Asian (81.6 %), the median age was 60.0 years, the baseline ECOG performance status was 0 (28.6 %) or 1 (71.3 %); one patient had a baseline ECOG performance status of 2.
Većina bolesnika su bili neazijati (81,6 %), medijan dobi je iznosi 60,0 godina, početna vrijednost statusa općeg stanja bolesnika prema ECOG-u je bila 0 (28,6 %) ili 1 (71,3 %); jedan bolesnik je imao početnu vrijednost 2 statusa općeg stanja bolesnika prema ECOG-u.